AMNEAL PHARMACEUTICALS, INC.
At today's price, AMNEAL PHARMACEUTICALS, INC. (AMRX) is priced for +7.9% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Amneal is shifting from a low-margin generics maker into a higher-value specialty and biosimilars company, and the single number that captures the transition is the specialty segment growing 23%, led by newer branded products in women's health, ADHD, and Parkinson's. • The defining risk is leverage: net debt sits near $2.4 billion, roughly 5.5 times operating income, the legacy of building the business with borrowed money, and deleveraging only works if adjusted EBITDA keeps climbing. • What t
Is AMRX overvalued? See what's priced in →
304 institutional managers reported holding AMRX in 13F filings for the quarter ended 2026-03-31. Together they hold about 48% of the company; the top 10 hold 29%. 70 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 7.9M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (3.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
AMRX's share count grew 112.1% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at AMRX over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
AMRX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | +4.3% | +70.2% |
| 2023-08-09 | +22.3% | -0.7% |
| 2023-11-10 | -3.6% | +28.0% |
| 2024-03-15 | -0.9% | +24.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
AMRX's latest 8-K filings: 2026-05-07 (items 5.07); 2026-05-07 (items 2.02, 9.01); 2026-04-22 (items 1.01, 2.02, 3.02, 7.01, 9.01); 2026-02-27 (items 2.02, 7.01, 9.01); 2026-02-03 (items 1.01, 2.03).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.